TickerHumSide-by-side comparison
Gilead Sciences vs Eli Lilly and
As of Nov 11, 2026, P/S is 6.8x for Gilead Sciences vs 15.6x for Eli Lilly and; revenue growth is 6.5% for Gilead Sciences vs 45.5% for Eli Lilly and; net margin is -12.5% for Gilead Sciences vs 31.9% for Eli Lilly and; debt/equity is 1.83 for Gilead Sciences vs 1.17 for Eli Lilly and.
What stands out
- Eli Lilly and is growing revenue faster: 45.5% vs 6.5% for Gilead Sciences.
- Eli Lilly and carries less debt relative to equity: 1.17 vs 1.83 for Gilead Sciences.
- Eli Lilly and scores higher on TickerHum's ratings: 70/100 vs 45/100 for Gilead Sciences.
Key metrics
| Metric | GILD | LLY |
|---|---|---|
| Price | $169.73 | $1,437.29 |
| Market cap | $210.52B | $1.35T |
| P/E | — | 46.7x (#1) |
| P/S | 6.8x (#1) | 15.6x (#2) |
| Revenue growth | 6.5% (#2) | 45.5% (#1) |
| Operating margin | -7.6% (#1) | — |
| Net margin | -12.5% (#2) | 31.9% (#1) |
| Debt / equity | 1.83 (#2) | 1.17 (#1) |
| 1-year return | +37.5% (#2) | +41.2% (#1) |
| Research score | 45/100 (#2) | 70/100 (#1) |
Higher is better for growth, margins, one-year return and overall score; lower is better for valuation and debt ratios. Ties share a rank and missing values are excluded.
Company research
- Gilead Sciences, Inc. (GILD) — Drug Manufacturers—General
- Eli Lilly and Company (LLY) — Drug Manufacturers—General